Pharmacokinetic interaction between raltegravir and rifampicin in an infant with HIV exposed to active TB: a case report

1Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We report a case of an infant with HIV receiving raltegravir granules for oral suspension and rifampicin-based TB prophylaxis. Raltegravir trough levels remained subtherapeutic and viral load increased during concurrent rifampicin therapy despite using double-dosed raltegravir. Even after rifampicin therapy, a higher dose was needed. This highlights the importance of therapeutic drug monitoring and dose adjustments of raltegravir in infants with rifampicin as comedication.

Cite

CITATION STYLE

APA

van der Veer, M. A. A., Jacobs, T. G., Bukkems, L. H., Colbers, A. P. H., Burger, D. M., Scherpbier, H. J., & Bijleveld, Y. A. (2022). Pharmacokinetic interaction between raltegravir and rifampicin in an infant with HIV exposed to active TB: a case report. Antiviral Therapy, 27(4). https://doi.org/10.1177/13596535221119932

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free